- Home
- VRXA vs NBP Comparison
VRXA vs NBP Comparison
Compare VRXA & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRXA | NBP |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.4M | 205.9M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VRXA | NBP |
|---|---|---|
| Price | $1.17 | $1.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 109.4K | ★ 621.9K |
| Earning Date | N/A | 08-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $1.31 |
| 52 Week High | $4.50 | $5.19 |
Technical Indicators
Market Signals| Indicator | VRXA | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 33.36 | 30.22 |
| Support Level | N/A | N/A |
| Resistance Level | $1.99 | $1.67 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 29.17 | 10.29 |
Price Performance
Historical ComparisonAbout VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.